Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES IZETTLE AB IN CONNECTION WITH CAPITAL RAISING
Mandate

VINGE ADVISES IZETTLE AB IN CONNECTION WITH CAPITAL RAISING

May 14, 2014

iZettle AB has carried out a directed new issue of approximately EUR 40 million to the private equity companies Zouk Capital, Dawn Capital and Intel Capital as well as to some of the company’s existing shareholders in order to develop its payment services solutions and continue its expansion within and outside Sweden.

iZettle AB makes it possible for businesses and private persons to receive card payments by downloading iZettle AB’s app to an iPhone or iPad (with or without a card reader).

Vinge’s team consisted of responsible partner Henrik Wenckert together with, among others, associates Malin Buch and Filip Brosset.  

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026